中国医药健康产业股份有限公司2025年度利润分配方案详解

主要内容摘要

• 公司拟在2025年度派发现金红利，每股合计人民币0.09491元（含税）。
• 利润分配以权益分派股权登记日登记的总股本为基数，若期间总股本发生变动，分配比例将保持不变，具体金额将调整并另行公告。
• 2025年度现金分红总额约为1.42亿元，占年度归属于上市公司股东净利润30%。
• 本次利润分配方案尚需提交股东会审议。
• 公司2025年度不实施公积金转增股本。
• 分红方案不触及上交所风险警示条款。
• 公司收购北京金穗科技开发有限责任公司100%股权，2024年财务数据已追溯调整。

详细解读

中国医药健康产业股份有限公司（证券代码：600056）近日公布了2025年度利润分配方案。根据董事会决议，公司拟以实施权益分派股权登记日登记的总股本为基数，向全体股东派发现金红利。

分红方案具体内容

• 末期现金红利为每10股0.7525元（含税），年度累计为每10股0.9491元（含税）。
• 以目前总股本1,495,879,748股计算，末期拟派发现金红利为112,564,951.04元，中期已派发29,408,995.85元，年度合计为141,973,946.89元。
• 2025年度现金分红占年度合并财报归属于上市公司股东净利润的30%。
• 母公司剩余未分配利润为2,443,549,725.99元，将结转以后年度分配。
• 若股权登记日前总股本发生变动，分配比例不变，金额调整并另行公告。
• 本次利润分配方案须股东会审议通过。

历史分红及财务数据

最近三个会计年度累计现金分红总额为617,035,437.26元，平均净利润为701,283,427.75元，现金分红比例为87.99%。公司未触及任何因分红比例过低而被实施风险警示的情形。

重大事项与风险提示

• 公司于2025年6月完成对北京金穗科技开发有限责任公司100%股权的收购，属于同一控制下企业合并，相关财务数据已追溯调整。
• 利润分配方案充分考虑公司现金流及资金需求，对经营现金流无重大影响，不影响公司正常经营和发展。
• 分配方案尚需股东会审议，投资者需关注后续进展。

投资者需关注的重点

• 现金分红方案将直接影响股东回报，且分红政策稳定，具有一定投资吸引力。
• 公司收购金穗科技对财务报表影响较大，投资者应关注整合后的业绩表现。
• 分红比例不触及风险警示条款，显示公司治理规范，财务状况良好。
• 方案尚未最终通过，存在一定不确定性。

结论

本次利润分配方案体现公司良好的盈利能力和现金流保障，分红政策稳定，对于投资者而言具有正面影响。公司重大资产收购及财务调整也值得持续关注。投资者应密切留意股东会审批及后续公告，合理评估投资风险。

免责声明

本文章仅供参考，不构成任何投资建议。请投资者根据自身情况及风险偏好谨慎决策，关注公司后续公告。

English Version

Detailed Analysis of China National Medicines Corporation Ltd. 2025 Profit Distribution Plan

Key Highlights

• The company plans to distribute a total cash dividend of RMB 0.09491/share (pre-tax) for 2025.
• Profit distribution is based on the total share capital registered on the equity distribution record date. If the share capital changes before that date, the distribution ratio remains unchanged, while the total amount will be adjusted and separately announced.
• Total cash dividend for 2025 is approximately RMB 142 million, accounting for 30% of the net profit attributable to shareholders.
• This proposal must be approved by the shareholders’ meeting.
• No capital reserve transfer to share capital will occur in 2025.
• The dividend plan does not trigger any risk warning clauses by the Shanghai Stock Exchange.
• The company acquired 100% equity in Beijing Jinsui Technology Development Co., Ltd., with 2024 financial figures retrospectively adjusted.

In-depth Analysis

China National Medicines Corporation Ltd. (stock code: 600056) has announced its 2025 profit distribution proposal. According to the board resolution, the company intends to distribute cash dividends to all shareholders based on the total share capital registered at the equity distribution record date.

Dividend Plan Details

• Year-end cash dividend is RMB 0.7525 per 10 shares (pre-tax), with a total annual dividend of RMB 0.9491 per 10 shares (pre-tax).
• Based on current total share capital of 1,495,879,748 shares, year-end dividend is RMB 112,564,951.04; mid-year dividend already paid is RMB 29,408,995.85; total annual dividend is RMB 141,973,946.89.
• 2025 cash dividend represents 30% of the net profit attributable to shareholders.
• Retained earnings of RMB 2,443,549,725.99 will be carried forward for future distribution.
• If share capital changes before the record date, the ratio stays the same, but the total distributed amount will be adjusted and separately announced.
• The plan requires shareholder approval.

Historical Dividend and Financial Data

Cumulative dividend in the last three years is RMB 617,035,437.26, with an average net profit of RMB 701,283,427.75 and a dividend ratio of 87.99%. The company does not trigger any risk warning due to low dividend ratio.

Major Matters & Risk Warning

• In June 2025, the company completed the acquisition of 100% equity in Beijing Jinsui Technology, counted as a business combination under common control; relevant financial data for 2024 has been retrospectively adjusted.
• The plan fully considers cash flow and capital needs, with no major impact on operational cash flow or business development.
• The plan is pending shareholder approval; investors should monitor subsequent developments.

Key Points for Investors

• The cash dividend policy directly affects shareholder returns and shows stability, which is attractive for investors.
• The acquisition of Jinsui Technology may significantly impact financial statements; investors should follow post-merger performance.
• The dividend ratio does not trigger any risk warning, reflecting sound corporate governance and financial health.
• The plan is not finalized, so there is some uncertainty.

Conclusion

This profit distribution plan demonstrates the company’s strong profitability and cash flow, with a stable dividend policy that positively impacts investor sentiment. The major asset acquisition and financial adjustments are noteworthy. Investors should closely follow the shareholder meeting approval and subsequent announcements, and assess investment risks accordingly.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own risk tolerance and stay alert to company announcements.

View 中国医药 Historical chart here